AdAlta Limited (ASX:1AD) is a clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging for other technologies.
What is an i-body?
An i-body is a unique human protein that combines the advantages of small molecules (for stability) and antibodies (with a high affinity and specificity for treating certain illnesses) in one powerful treatment. The i-body has a unique long loop that can bind to a diverse range of targets meaning that it has wide applicability across many diseases.
AdAlta’s internal pipeline is focused on GPCRs implicated in fibrotic and inflammatory disease and cancer and its external pipeline is leveraging partner expertise to pursue a wider range of targets and indications.
The Company’s first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. There is a high-unmet medical need for effective treatments. AdAlta commenced a human Phase 1 clinical trial for AD-214 in July 2020.
AdAlta is continuing further discovery and development of the i-body platform, directed towards other disease targets for in-house development or partnering.
Corporate Overview
AdAlta listed on the ASX (ASX: 1AD) in August 2016. The Company is led by an experienced management team and Board and is supported by a world class scientific advisory board.
Both AdAlta’s i-body technology platform and lead asset, AD-214, are protected by a strong portfolio of worldwide granted patents and pending applications.